Application of semi-industrial monolithic columns for downstream processing of clotting factor IX

被引:26
作者
Branovic, K
Buchacher, A
Barut, M
Strancar, A
Josic, D
机构
[1] Octapharma Pharmazeut Prod GesmbH, A-1100 Vienna, Austria
[2] BIA Separat Doo, Lab & Proc Equipment Co Ltd, Ljubljana 1000, Slovenia
[3] Univ Zagreb, Inst Immunol, Zagreb 10000, Croatia
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2003年 / 790卷 / 1-2期
关键词
monolithic columns; preparative chromatography; factor IX; vitronectin;
D O I
10.1016/S1570-0232(03)00095-3
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
It has been shown in a previous study that monolithic columns can be used for downstream processing of different concentrates of clotting factor IX [K. Branovic et al., J. Chromatogr. A 903 (2000) 21]. This paper demonstrates that such supports are useful tools also at an early stage of the purification process of factor IX from human plasma. Starting with the eluate after solid-phase extraction with DEAE-Sephadex, the use of monolithic columns has allowed much better purification than that achieved with conventional anion-exchange supports. The period of time required for separation is also much reduced. In up-scaling experiments, separations are carried out with 8, 80 and 500 ml columns. A volume of 1830 ml of DEAE-Sephadex eluate, containing a total of 27.6 g of protein and 48 500 IU of factor IX is applied to the 500 ml monolithic column. This corresponds to a separation on a pilot scale. The results of this separation after up-scaling are comparable to those obtained with the 8 ml column on a laboratory scale. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:175 / 182
页数:8
相关论文
共 22 条
[1]   Application of monoliths for downstream processing of clotting factor IX [J].
Branovic, K ;
Buchacher, A ;
Barut, M ;
Strancar, A ;
Josic, D .
JOURNAL OF CHROMATOGRAPHY A, 2000, 903 (1-2) :21-32
[2]  
BRANOVIC K, 2001, THESIS U ZAGREB CROA
[3]  
Burnouf T., 1991, BIOSEPARATION, P383
[4]   HIGH-SPEED HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY OF PEPTIDES AND PROTEINS [J].
CHEN, H ;
HORVATH, C .
JOURNAL OF CHROMATOGRAPHY A, 1995, 705 (01) :3-20
[5]  
CLARKE SG, 2002, IBC C IMP POST TRANS
[6]   IMPROVED VIRUS SAFETY AND PURITY OF A CHROMATOGRAPHICALLY PRODUCED FACTOR-IX CONCENTRATE BY NANOFILTRATION [J].
HOFFER, L ;
SCHWINN, H ;
BIESERT, L ;
JOSIC, D .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1995, 669 (02) :187-196
[7]   Production of highly purified clotting factor IX by a combination of different chromatographic methods [J].
Hoffer, L ;
Schwinn, H ;
Josic, D .
JOURNAL OF CHROMATOGRAPHY A, 1999, 844 (1-2) :119-128
[8]  
Iberer G, 1999, LC GC N AM, V17, P998
[9]   Continuous purification of a clotting factor IX concentrate and continuous regeneration by preparative annular chromatography [J].
Iberer, G ;
Schwinn, H ;
Josic, D ;
Jungbauer, A ;
Buchacher, A .
JOURNAL OF CHROMATOGRAPHY A, 2002, 972 (01) :115-129
[10]   Improved performance of protein separation by continuous annular chromatography in the size-exclusion mode [J].
Iberer, G ;
Schwinn, H ;
Josic, D ;
Jungbauer, A ;
Buchacher, A .
JOURNAL OF CHROMATOGRAPHY A, 2001, 921 (01) :15-24